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ambulatory and in a compensated stage. Compared with the Japanese
norm, our CHF patients showed global reductions in SF-36 PCS,MCS, and
RCS except for MCS in NYHA I patients. Although the most pronounced
loss of HRQOLwas observed in the domain of physical problems relating
to symptoms of shortness of breath, SF-36 subscale scores relating to
mental status (vitality and mental health) and role status (role-
emotional and social functioning) were also low. Thus, both mental
status and role status must be considered in CHF outpatients, and the
effect of CR on these aspects must be evaluated in longitudinal
settings and for longer periods in the future.
The authors of this manuscript have certiﬁed that they comply with
the Principles of Ethical Publishing in the International Journal of
Cardiology [5].
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Hypertension is a complex disorder commonly associated with
atherosclerosis and cardiovascular events. In recent years, the link
between hypertension and inﬂammation became clear as suggested by
several experimental [1,2] and observational [3,4] studies.
Adaptive immunity seems deeply involved in the modulation of
atherosclerosis development depending on the type of T-lymphocytes
and phagocytes involved [5]. Furthermore, the elevated autoantibodies
against oxidized LDLwere reported in hypertension [6], aswell as in the
pre-hypertensive stage [7] associated with clinical conditions.
Several assays have been developed to quantify the circulating
oxidized LDL and their relations to cardiovascular disease [8,9]. In
addition, evaluation of new antibodies have been proposed to evaluate
more speciﬁc epitopes of the modiﬁed LDL [10,11].
Taking into account that uncontrolled hypertension is closely related
to cardiovascular events, we hypothesized a link between blood
pressure levels and some parameters of the adaptive immunity among
hypertensive subjects.
A total of 58 individuals of both genderswith establisheddiagnosis of
hypertensionwere consecutively included in the study. All patientswere
under anti-hypertensive treatment (alone or combined) with
angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor
blocker (ARB) or diuretics (mainly hydrochlorothiazide). We excluded
subjects with diabetes mellitus, those with renal or liver disease, or
presenting acute or chronic inﬂammatory disease. We also excluded
smokers, those under hormone replacement therapy, statin therapy or
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Table 1
Major characteristics of the study population.
Better BP control
(n=29)
Poorer BP control
(n=29)
P-value
Age, years, median (IQR) 60 (50–67) 56 (53–65) 0.95
Male gender, n (%) 19 (65) 16 (55) 0.09
BMI, kg/m2, median (IQR) 27.9 (25.1–31.2) 27.5 (25.1–29.5) 0.76
SBP, mm Hg, median (IQR) 137 (129–149) 160 (150–165) b0.001
DBP, mm Hg, median (IQR) 80 (79–90) 100 (89–101) b0.001
Glucose, median (IQR) 86 (76–91) 96 (92–102) b0.001
Cholesterol, median (IQR) 184 (162–223) 207 (183–233) 0.07
LDL-C, median (IQR) 117 (89–134) 130 (111–151) 0.06
HDL-C, median (IQR) 46 (39–60) 51 (42–58) 0.92
TG, median (IQR)* 100 (69–147) 119 (87–186) 0.38
Creatinine, median (IQR) 1.0 (0.8–1.1) 0.8 (0.6–1.0) 0.11
GFR, median (IQR) 83 (64–114) 68 (62–82) 0.01
ACEI/ARB, n (%) 29 (100) 19 (66) b0.001
Diuretics, n (%) 0 (0) 15 (52) 0.001
IQR= interquartile range; BMI= bodymass index; SBP= systolic blood pressure; DBP=
diastolic blood pressure; GFR = glomerular ﬁltration rate (Cockcroft–Gault, ml/min/
1.73 m2); TG = triglycerides; ACEI = angiotensin converting enzyme inhibitor; ARB =
angiotensin receptor blocker; glucose, cholesterol, LDL-C, HDL-C, TG and creatinine are
expressed in mg/dL;*values were log-transformed. Comparisons were made by the
unpaired Student's t test.
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with previous history of cancer. The study was approved by the local
Ethics Committee of our university, and informed consent was obtained
from all patients prior to protocol initiation.
Twelve-hour fasting sampleswere obtained for all patients. Glucose,
total cholesterol, high-density lipoprotein cholesterol and triglycerides
were determined enzymatically (Opera Bayer, Leverkusen, Germany),
and LDL-cholesterol was estimated by the Friedewald equation [12].
Plasma peroxidation was evaluated by the thiobarbituric acid-reactive
substances (TBARS) assay, which measures malondialdehyde [13].
Glomerular ﬁltration rate (GFR) was estimated by the Cockcroft–Gault
equation [14].
Preparationof oxidized LDLmeasurementwaspreviously reported [9].
Todetermine theabs to copper-oxidizedLDL,weusedanestablishedassay
as previously described [15]. To minimize false positive results due to
cross-reactivity with antigen naive epitopes, abs titers were expressed as
the reactivity index (RI), calculated as, RI=(ODsample−ODsample blank)/
(ODIgG−ODIgG blank)where IgGwasusedasacontrol. Sampleswere run in
triplicate and the variationwithin the triplicates did not exceed 5% of the
mean.
Autoantibodies anti-apoB epitope derived from ApoB100 of LDL
(anti-apoB-D abs) were measured by ELISA [15]. The apoB-D is a 22
Table 2
Oxidative, inﬂammatory and immune parameters per group.
Better BP control
(n=29)
Poorer BP control
(n=29)
P-value
IL-6 (pg/ml)*, median (IQR) 7.5 (6.8–9.5) 12.1 (6.9–16.1) 0.50
IL-8 (pg/ml)*, median (IQR) 2.2 (1.3–4.2) 2.8 (2.5–3.9) 0.02
IL-10 (pg/ml)*, median (IQR) 9.1 (8.6–11.1) 4.1 (3.9–4.7) b0.001
TBARS (μmol/ml), median (IQR) 1.3 (0.8–1.2) 1.5 (1.2–1.9) 0.29
Anti-oxLDLabs (RI)*, median (IQR) 1.7 (1.3–2.2) 1.2 (1.2–1.3) b0.001
Anti-apoB-D (RI)*, median (IQR) 0.5 (0.2–0.6) 0.9 (0.8–1.0) 0.002
IQR= interquartile range; IL-6= interleukin 6; IL-8 = interleukin 8; IL-10 = interleukin
10; TBARS = Thiobarbituric acid-reactive substance; AntioxLDL abs = anti oxLDL
autoantibodies; Anti-apo B-D = antibodies antiapoB- D peptide; RI = Reactivity index; *
log-transformed variables.
Comparisons between groups were made by the unpaired Student's t test.
Fig. 1. Scatter plots showing correlations between anti-OxLDL autoantibodies (abs) and systolic (SBP) (A) and diastolic (DBP) blood pressures (B). There was an inverse correlation
between anti-oxLDL abs and both SBP (rho=−0.379, P=0.004) and DBP (rho=−0.425, P=0.002). Scatter plots showing correlations between the apoB-D peptide and systolic
(SBP) (C) and diastolic (DBP) blood pressures (D). Therewas a positive correlation between the antibodies against the apoB-D peptide and blood pressure. An inverse correlationwas
obtained between apoB-D abs and both SBP (rho=0.558, Pb0.001) and DBP (rho=0.335; P=0.01). Scatter plots showing correlations between interleukin-10 (IL-10) and oxLDL abs
(E) and anti-apo B-D abs (F). There was a positive correlation between IL-10 with oxLDL abs titers (r=0.444, P=0.001), and an inverse correlation with anti-apo B-D abs (r=−0.501,
P=0.004). RI = reactivity index. All correlations were made by Spearman's correlation test.
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amino acid peptide from a region of apoB-100 not accessible to trypsin,
and has been proposed as an independent predictor of atherogenic
processes. To determine the abs to apoB-D,we usedour own established
assay as previously described [10].
The pro-inﬂammatory cytokines, interleukin 6 (IL-6) and interleukin
8 (IL-8), as well as the anti-inﬂammatory interleukin 10 (IL-10) were
measured by ELISA, according to the information provided by the
manufacturer (R&D Systems, Minneapolis, MN).
Blood pressure (BP)was evaluated as previously reported [6]. Brieﬂy,
an average of three measurements of sitting BP obtained after a 5-min
resting period and repeated at 5-min intervals was recorded. For
comparisons, the BP obtainedwas used to form two groups, considering
those with better and poorer BP control (according to the 50th
percentile).
Numerical data were reported as median values and interquartile
range, or means and SEM. Categorical variables were expressed as
number of subjects and percent values. Variables with non-Gaussian
distributionwere log-transformed for comparisons. Unpaired Student's t
test was used for independent comparisons between groups, and
Pearson χ2 test was used for categorical variables. Correlations between
variables were tested by Spearman test. A P value of b0.05 was
considered signiﬁcant. Statistical Package for the Social Sciences
software (version 17.0 SPSS Inc; Chicago, IL), was used in all analysis.
Major characteristics of the study population are shown in Table 1.
Subjects were predominantly middle-aged, overweight males. There
were small differences on biochemistry parameters or antihypertensive
strategies, and the major differences were in the BP control.
Compared to poorer BP control, we observed lower titers of IL-8 and
higher titers of IL-10 in the group of better BP control. No differences
between groups were seen for IL-6 and TBARS (Table 2). Inverse
relationship was observed between the IL-10 and both systolic and
diastolic BP.
Subjects in the group of better BP control had higher titers of
anti-oxLDL abs and lower titers of anti-apoB abs (Table 2). In addition,
we observed inverse correlation between systolic and diastolic BP levels
and the titers of anti-oxLDL abs (Fig. 1A–B). Conversely, the titers of the
anti-apoB-D abswere positively correlatedwith systolic and diastolic BP
(Fig. 1C–D). Furthermore, we also observed correlation between the
titers of IL-10with the titers of anti-oxLDL abs and inverse correlation of
IL-10with the titers of the anti-apoB-D abs (Fig.1E–F). Finally, regarding
the titers of TBARS, we observed an inverse associationwith the titers of
the anti-oxLDL abs (rho=−0.35, Pb0.01, Spearman test), while the
anti-apoB-D abs were correlated with the titers of IL-8 (rho=0.377;
Pb0.005, Spearman test).
In conclusion,we reported a linkbetweenhypertension andadaptive
immunity responses to OxLDL and peptides of Apo B 100. Our results
suggest that BP values are correlated with the inﬂammatory and
immune milieu. Further studies are needed to identify products of LDL
oxidation as potential biomarkers of coronary disease as well as their
role in the modulation of atherosclerosis in hypertensive patients.
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the Principles of Ethical in Publishing in the International Journal of
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